Amanda Cole, Director of the Office of Health Economics, warns that the United Kingdom’s exit from the EU has stripped away a vital safety net, leaving the NHS increasingly exposed to medicine shortages. In a letter to the editor she argues that the loss of access to EU medicine reserves, combined with tangled cross‑border logistics, has heightened vulnerability, particularly for off‑patent generic and biosimilar drugs. She stresses that while low prices drive health‑system savings, pushing them too low forces manufacturers out of the market, creating fragile supply chains that can snap under any surge in demand or disruption.
Impact of Brexit on Medicine Supply Chains
Cole points out that the UK no longer benefits from the EU’s pooled medicine reserves, a buffer that once helped smooth sudden spikes in need or interruptions in production. She notes that hospitals in England have already reported shortages of everyday medicines such as paracetamol, a situation highlighted on 29 September. The geopolitical shift has added layers of complexity to importing active pharmaceutical ingredients and finished products, making the supply chain more sensitive to any political or logistical shock.
The Risks of Ultra‑Low Drug Prices
The letter highlights research showing that shortages are concentrated in markets for off‑patent generics and biosimilars, where price competition is fiercest. Cole explains that when regulators or purchasers drive prices to an unsustainable low, manufacturers withdraw, leaving only a handful of suppliers. This concentration means that a single factory outage or a sudden rise in prescriptions can trigger a national shortage. When shortages occur, the NHS faces higher emergency procurement costs, reliance on pricier alternatives, and a substantial administrative burden, while patients experience delayed treatment and poorer health outcomes.
Policy Recommendations for Resilient Supply
Cole urges the government to strike a balance between affordability and security. She recommends using regulatory tools, pricing frameworks, and approval processes to encourage competition and build supplier resilience rather than pursuing relentless price cuts. By safeguarding a diverse manufacturer base and maintaining strategic reserves, the UK can protect both the NHS budget and patient access to essential medicines.
Why it Matters
The convergence of Brexit‑induced supply fragility and aggressive price‑cutting threatens to turn occasional drug shortages into a chronic problem that undermines NHS efficiency and patient safety. Without decisive action to nurture a competitive, resilient medicines market, the health service will continue to bear the hidden costs of emergency procurement, while patients risk avoidable harm from delayed or inadequate treatment. Striking the right balance now is essential to safeguard public health and maintain trust in the UK’s pharmaceutical system.
